Preclinical toolkit evolution for cancer vaccines & CAR-T cell therapy

Cell & Gene Therapy Insights 2023; 9(1), 41–47

DOI: 10.18609/cgti.2023.005

Published: 18 January 2023
Adam Snook

David McCall, Commissioning Editor, BioInsights, speaks to Adam Snook, Associate Professor, Department of Pharmacology, Physiology & Cancer Biology, Thomas Jefferson University

Adam Snook is currently an Associate Professor in the Department of Pharmacology, Physiology, & Cancer Biology with a secondary appointment in the Department of Microbiology & Immunology. He is an Assistant Program Leader of the Immune Cell Regulation and Targeting (IRT) Program of the Sidney Kimmel Cancer Center and Director of the Clinical & Translational Research track of the JeffMD Scholarly Inquiry Program of the Sidney Kimmel Medical College. He received a BSc in Pharmacology and Toxicology (2001) from the University of the Sciences and a PhD in Immunology and Microbial Pathogenesis (2008) from Thomas Jefferson University. After postdoctoral work in academia and industry, he joined the faculty at Thomas Jefferson University in 2013 where he is developing new options to prevent or treat gastrointestinal cancers. His work has led to seven investigator-initiated clinical trials examining cancer chemoprevention, cancer vaccines, and CAR-T cell therapies